Sun Pharmaceutical Industries Ltd - Research Report


Private Client Research




Pharmaceuticals & Drugs


Sun Pharmaceutical Industries Ltd

Reco Price
Rs. 611.00
Price Target (1 Year)
Rs. 734.00


Nov 09, 2016
CNX Nifty




FDA approval for the Halol plant will increase revenues and profitability for the company.

Integration of Ranbaxy:
In March 2015, Sun Pharma had completed the acquisition of Ranbaxy, creating India’s largest and the world’s fifth largest drug maker. The integration between the India businesses of both Sun Pharma and Ranbaxy is on-track; the major realization of the targeted synergies of $300 million is expected to be accrued in FY2017 and be completed during FY2018.

The company plans to increase the R&D productivity and introduce innovative products to increase the share of value-added products. The company will possibly evade very competitive and low margin products. This will have an impact on top line, but it will also potentially improve the overall percentage of cost of goods. They are also in process to try and improve the cost; followed by an increase in the usage of the facility. So what is being bought from outside, will now be produced in house.

Japanese market penetration:
The company has acquired 14 Novartis brands in Japan. This was a strategic business decision for the company in order to create a base to enter the Japanese market in the future. The Japanese acquisition will start contributing to the revenues of the company from the second half of FY17.

Halol Plant:
The company has been working towards remedying the problems that were identified during the FDA inspection in September 2014. They have been strictly adhering to the timelines and are on the brink of completing these remedial measures at the Halol Plant. Further to which, the company would request a USFDA re-inspection during the first quarter of FY17. In addition, the company has also been gradually increasing its capacity at the Halol Plant irrespective of the re-inspection process. The Halol plant makes up about 15 percent of Sun Pharma’s sales in its largest market, the United States. It is critical to the company as it has the capabilities to manufacture injectable products, which are difficult to manufacture and hence cater to a fairly niche and lucrative market for drug makers.

Further capex plans for development of psoriasis drug:
Sun Pharma acquired worldwide rights to “Tildrakizumab” for use in all human indications from Merck in exchange for an upfront payment of $80 million, milestone payments and tiered royalties. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon final approval for the product, Sun Pharma will be responsible for all subsequent activities. The drug is currently being evaluated in Phase 3 trials to treat chronic plaque psoriasis, a skin ailment. Sun is planning a capex of $250 million for Tildrakizumab, the IL-23 monoclonal anti-body in-licensed from MSD (US) over four to five years to be utilized for its psoriasis trials.

The company’s revenues grew at a 5 year CAGR of 37% to Rs. 27744 crores, while the EBIDTA grew at a CAGR of ~33% to Rs. 7956 crores and the PAT grew at a CAGR of ~25% to Rs. 5830 crores in FY16. The company also showed returns on equity and capital employed post tax at an average of 25% each.At CMP of Rs. 750, the stock is trading at 21.3x to FY 2018E which is low valuation for the company. We assign a “BUY” rating on stock with target price of Rs. 900 where it trades at 25.5x, which is fair valuation for the stock in the long term.

Stock Data

CMP (Rs)
Face value (Rs)
52 Week Range (Rs)
898.45 - 632.30
Market cap (Rs Crores)
Price To Book Value (x)
P/E Ratio (x)

One Year indexed Stock Performance

Sun Pharmaceutical Industries LtdSensex
Sun Pharmaceutical Industries Ltd
Return (%)


(in %)

+91 22 6639 3000



The Indian Pharmaceutical market has witnessed the kind of growth that no other sector has experienced in the last 1-2 decades. The sector is currently valued at around $27 Billion, i.e. ~ 3% of the global pharmaceutical industry in terms of value and 10% in terms of volume. It is poised to reach $55 Billion in the next 4 years. The Generic Drugs segment dominates the market with a 70% share in terms of revenues making it the largest segment in the Indian pharmaceutical sector. Similarly, Over-The-Counter (OTC) medicines constitute close to 21% and Patented Drugs occupy the remaining 9% of the total market. Indian pharmaceutical market grew at a handsome CAGR of 17.5% over the past 10 years. It is now expected to grow by 15% annually over the next 5 years as against the global growth estimate of just 5%. Currently, India is second after the US for highest number of US Food and Drug Administration (USFDA) approved plants in the world. This is huge in itself as 22% of such plants in the world are Indian. Additionally, India has 1400 plants that have been approved by the World Health Organization Good Manufacturing Practices (WHO GMP) and 253 by the European Directorate of Quality Medicines (EDQM).


Sun Pharma is a global specialty pharmaceutical company, with a large presence in the US and India, and a footprint across 40 other countries. In Indian formulations, the company is a leader in niche treatment areas of psychiatry, gastroenterology, neurology, cardiology, nephrology, orthopedics & ophthalmology. The US business has been built typically on acquisitions and generic focus. It owns the largest product portfolio amid Indian players with as many as 572 product (ANDA) filings; 413 approved and 159 pending approval in the pipeline.

Profit & Loss Statement:- (Consolidated)
(Rs Crores)
  • Net Sales
  • Growth (%)
  • Total Expenditure
  • % Margin
  • Other Income
  • Operating Profit
  • Interest
  • PBDT
  • Depreciation
  • PBT
  • Tax
  • Tax Rate (%)
  • Profit After Tax
  • Margin (%)
  • PAT Growth (%)
  • Adjusted EPS
  • 16080
  • 42.3
  • 9121
  • 6959
  • 43
  • 593
  • 7552
  • 44
  • 7508
  • 409
  • 7099
  • 702
  • 9.9
  • 6396
  • 39.8
  • 57.6
  • 15.17
  • 27433
  • 70.6
  • 19682
  • 7751
  • 28
  • 663
  • 8414
  • 579
  • 7835
  • 1195
  • 6641
  • 915
  • 13.8
  • 5726
  • 20.9
  • -10.5
  • 21.92
  • 27744
  • 1.1
  • 19788
  • 7956
  • 29
  • 459
  • 8941
  • 477
  • 7779
  • 1014
  • 6765
  • 935
  • 13.8
  • 5830
  • 21.0
  • 1.8
  • 19.60
  • 30426
  • 9.7
  • 19752
  • 10674
  • 35
  • 0
  • 10674
  • 528
  • 10146
  • 1038
  • 9108
  • 1457
  • 16.0
  • 7651
  • 25.1
  • 31.2
  • 31.79
  • 35940
  • 18.1
  • 24120
  • 11820
  • 33
  • 0
  • 11820
  • 502
  • 11318
  • 1092
  • 10226
  • 1738
  • 17.0
  • 8487
  • 23.6
  • 10.9
  • 35.27
Source: Stockaxis Research, Company Data


At CMP of Rs. 750, the stock is trading at 21.3x FY 2018E. The FDA approval at the Halol plant will unlock the shareholders value along with the integration of Ranbaxy; we expect a target price of Rs. 900 where it trades at 25.5x, which is fair valuation for the stock in the long term.



Opulent Investment Adviser Private Limited is registered as an Investment Adviser with SEBI bearing registration Number INA000002462 as per Securities and Exchange Board of India (Investment Advisers) Regulations, 2013. Opulent Investment Adviser Private Limited offer investment advisory services to clients as well as prospects.

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Opulent Investment Adviser Private Limited and its Research Analyst with reference to the subject company(s) covered in this report-:

Opulent Investment Adviser Private Limited does have any financial interest in the subject company: (NO)

Research Analyst or his/her relative’s have financial interest in the subject company: (NO)

Opulent Investment Adviser Private Limited and Research Analyst or his/her relative’s does have any material conflict of interest in the subject company: (NO)

Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: (NO)

The research Analyst has served as officer, director or employee of the subject company: (NO)

Our salespeople and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein.

This report is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person.

This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It is for the general information of the users of / Opulent Investment Adviser Private Limited.

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and we do not warrant its accuracy or completeness.

Opulent Investment Adviser Private Limited, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report.